Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10
21 mars 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy
19 févr. 2019 07h30 HE
|
Provectus Biopharmaceuticals Inc.
Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
12 févr. 2019 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
ARTICLE COMPARING SURVIVAL OUTCOMES OF ISOLATED LIMB INFUSION VERSUS PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
29 janv. 2019 08h30 HE
|
Provectus Biopharmaceuticals Inc.
- 72 patients were treated with either ILI or PV-10 at Australia’s Princess Alexandra Hospital; data were prospectively recorded; primary outcome was melanoma-specific survival; ILI is historical...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10
06 déc. 2018 08h30 HE
|
Provectus Biopharmaceuticals Inc.
Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA® (pembrolizumab) presented at...
PROVECTUS BIOPHARMACEUTICALS PROVIDES DRUG DEVELOPMENT UPDATE FOR IMMUNO-DERMATOLOGY ASSET PH-10
14 nov. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on the Company’s small molecule clinical development program for its investigational...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
12 nov. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR NEUROBLASTOMA
05 nov. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS
25 oct. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
- Single-agent adverse effect profiles of PV-10 and Keytruda were maintained - 65% overall objective response rate with 9% complete response, via RECIST 1.1 KNOXVILLE, TN, Oct. 25, 2018 ...
PROVECTUS ANNOUNCES PRESENTATION OF DATA FROM METASTATIC UVEAL MELANOMA COHORT OF PHASE 1 STUDY OF PV-10 IN LIVER CANCERS AT SMR 2018 CONGRESS
24 oct. 2018 16h15 HE
|
Provectus Biopharmaceuticals Inc.
- Assessing adverse event and preliminary efficacy profiles of PV-10 as single-agent and in combination with immune checkpoint inhibition for treatment of liver metastases KNOXVILLE, TN, Oct....